Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is part of City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help patients through efficiency and effectiveness of the translational process. For more information, visit: tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen. | About TGen, part of City of Hope Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is part of City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help patients through efficiency and effectiveness of the translational process. For more information about TGen, follow us on Facebook, BlueSky, Instagram and LinkedIn.
TheraFluor
TheraFluor, Inc. Overview TheraFluor, Inc. is a privately held theranostic company pioneering the targeted use of innovative nanomedicines to improve health outcomes for cancer patients. The company is developing a cutting-edge technology platform for cancer detection, fluorescence-guided surgery (FGS), and phototherapy (PT), designed to maximize patient benefits while minimizing side effects. Headquartered in Portland, Oregon, TheraFluor was founded on intellectual property from Oregon State University and is working to bring its proprietary nanoparticle technology and specialized instruments to both human and veterinary medicine markets. For more information, visit www.therafluor.com. Innovative Solutions for Cancer Treatment TheraFluor’s novel approach transforms the way surgeons detect, remove, and treat cancer. Our technology enables surgeons to more effectively distinguish between healthy and malignant cells in solid tumors during fluorescence-guided surgery (FGS), leading to cleaner margins and lower recurrence rates. At the heart of this technology is our patented tumor-activatable near-infrared (NIR) nanoparticle (SiNc-NP), which becomes fluorescent when it accumulates in solid tumors. SiNc-NP is an innovative, dual-function nanomedicine that combines fluorescent-imaging and phototherapeutic capabilities with both photodynamic therapy (PDT) and photothermal therapy (PTT) properties, enabling it to both guide tumor removal and kill residual cancer cells post-surgery. Encapsulated in biodegradable nanoparticles, this smart nanomedicine is activated in tumors and offers significant advantages over current FDA-approved fluorescent agents. SiNc-NP is non-toxic with enhanced fluorescent and photostable properties, enabling more precise surgery and tumor resection. Additionally, TheraFluor’s proprietary NIR camera system delivers high-quality visualization of both healthy and malignant tissue, making FGS technology accessible to every surgeon. Our software, powered by real-time images from the NIR camera, assists surgeons in achieving complete tumor resection. A Strong Business Model: Veterinary and Human Medicine Our strategy involves pursuing a dual-market approach. We are initially focusing on the veterinary market, where regulatory hurdles are lower and the path to revenue is faster. In parallel, we are looking for a strategic partner or to license our technology for use in human medicine to a commercial partner, advancing these products toward human clinical applications. This parallel approach will provide synergistic benefits for both regulatory paths. Veterinary Applications: Targeting Companion Animal Cancer TheraFluor is committed to improving the way veterinarians detect and treat cancer in dogs and cats. Cancer rates in pets, especially dogs, are high—often higher than in humans. Surgery is the primary treatment for most solid tumors, but challenges remain in achieving clean margins during surgical resection. A major unmet need exists in veterinary oncology, particularly for addressing tumors such as mast cell tumors (MCTs), which are the most common malignant tumors in dogs. MCTs are difficult to remove completely, with recurrence rates of 30% to 64% if clean margins aren’t achieved. The need for repeat surgeries or follow-up chemotherapy and radiation therapy drives up costs for pet owners and can lead to shortened lifespans for pets. Initial studies have demonstrated the optimal dosage of SiNc-NP for targeting MCTs in both mouse models and canines. SiNc-NP was found safe for use in dogs over an ~30-fold dose range with no adverse events. Furthermore, SiNc-NP helped the surgical veterinarian identify additional MCTs (~25%) that were not known prior to SiNc-NP administration. Path to Regulatory Approval and Future Growth TheraFluor is focusing on gaining approval from the Center for Veterinary Medicine for our SiNc-NP product. This regulatory process is expected to take 3-5 years and will cost between $3-5 million. Instrument development and scaling for market will require an additional $2-3 million. TheraFluor’s long-term vision includes expanding into human medicine through strategic partnerships/licensing and leveraging our proven technology to make a significant impact on both veterinary and human oncology markets. Market Opportunity in Human Oncology: Ensuring Clean Margins in Tumor Resection The challenge of achieving clean margins during tumor resection is a significant issue in human oncology as well. For many solid tumors, the success of surgery depends on completely removing the cancerous tissue, with any remaining cancer cells leading to recurrence and potentially fatal outcomes. Despite advancements in imaging techniques, surgeons often struggle to clearly distinguish between healthy and malignant tissue, especially in complex or deeply embedded tumors. TheraFluor’s innovative technology offers a promising solution by providing real-time fluorescence-guided visualization, enabling surgeons to more accurately identify tumor boundaries and improve surgical precision. Additionally, the SiNc-NP’s phototherapeutic properties will enable surgeons to eliminate residual cancer cells in the surgical bed significantly reducing recurrence rates and the need for follow-up treatments, such as additional surgeries or radiation therapy, ultimately improving patient survival and quality of life. The market for surgical aids aimed at improving tumor margin delineation is substantial, with growing demand for advanced technologies in cancer surgery. As the global incidence of cancer continues to rise, particularly in complex cancers like gliomas, breast cancer, and sarcomas, the potential for TheraFluor’s platform in human oncology is vast, offering a major opportunity to enhance surgical outcomes and lower overall healthcare costs. Near-Infrared Imaging Systems for Surgical Guidance Near-infrared (NIR) imaging systems are emerging as powerful tools in the field of surgical guidance, providing real-time, high-resolution visualization of tissues during surgery. These systems utilize NIR fluorescence to highlight specific tissues or tumors, enabling surgeons to differentiate between healthy and malignant cells with greater accuracy than traditional imaging techniques. NIR imaging offers several advantages, including deep tissue penetration, minimal tissue damage, and the ability to visualize tumors that are otherwise difficult to detect with the naked eye. By incorporating NIR fluorescent agents, such as those developed by TheraFluor, these systems can enhance the precision of tumor resections, ensuring that cancerous tissues are completely removed while preserving surrounding healthy tissues. As a result, NIR imaging is increasingly being adopted in cancer surgeries, offering the potential to reduce recurrence rates, improve surgical outcomes, and shorten recovery times. With the growing adoption of minimally invasive surgery and a shift towards precision medicine, the market for NIR imaging systems is expected to expand rapidly, representing a significant opportunity for companies like TheraFluor that are innovating in this space. Team and Funding TheraFluor has assembled a talented team with deep expertise in biotechnology, fluorescent chemistry, regulatory affairs, and market strategy. We have also assembled a strong advisory network, including key inventors, veterinary experts, and collaborators at Oregon State University. TheraFluor has received significant funding from Oregon Nanoscience and Microtechnologies Institute (ONAMI) and two SBIR Phase 1 grants. We are applying for additional non-dilutive funding through SBIR Phase 2 programs to advance dye and instrument development. We are actively raising a seed round from angel investors that will be followed by a larger Series A round in two years. Licensing Opportunity: A Strategic Advantage for Partners TheraFluor’s proprietary near-infrared (NIR) imaging and therapeutic platform offers a unique and highly differentiated solution in the rapidly evolving oncology space, making it an attractive licensing opportunity for companies looking to advance cancer treatment technologies. With its dual functionality—providing both real-time tumor visualization and therapeutic capabilities—our technology has the potential to significantly enhance surgical outcomes, reduce recurrence rates, and improve patient survival across both veterinary and human medicine. By licensing this cutting-edge technology, companies can quickly enter the lucrative human oncology market with a proven, patent-protected solution, bypassing the long and costly development cycles typically associated with new medical technologies. Moreover, as the global oncology market continues to grow, particularly in minimally invasive and precision surgeries, this technology offers a strategic advantage for partners seeking to differentiate themselves in a competitive landscape. TheraFluor is actively seeking commercial partners to license its technology, providing them with a high-impact, innovative tool that can transform cancer treatment and position them at the forefront of the next generation of medical advancements.
TAMASERV GmbH
TAMASERV is dedicated to advancing scientific research through developing and providing cutting-edge tools around RNA modifications. Our expertise lies in epitransriptomic solutions for RNA-based applications, supporting biotech and academics in unlocking new frontiers in molecular biology. With a strong commitment to precision and efficiency, we collaborate with partners around the globe to enhance RNA research and therapeutic developments. Expanding our vision, we have recently launched an ambitious crop yield improvement project. Leveraging our RNA modification expertise we are taking a dive into agricultural productivity and resilience. Recent high-profile research suggests that specific RNA modifications can serve as molecular predictors of crop resilience and yield. By integrating these insights with advanced analytics, we aim to develop novel strategies for improving agricultural products, particularly in regions with changing climate conditions. Partner with us in shaping the next generation of biotechnological advancements through unlocking the potential of RNA Modifications.
SyntheticGestalt KK
“DRUG DISCOVERY REIMAGINED: 90% LESS COST, 75% LESS TIME” [PIONEERING MOLECULAR AI INNOVATION] SyntheticGestalt has developed the world’s largest molecule-specialized AI foundation model, revolutionizing drug discovery and molecular design across industries. Founded in 2018 in Tokyo, we’re addressing a critical challenge: early-stage pharmaceutical R&D consumes 40% of total drug development costs while traditional AI approaches struggle with limited datasets and technical barriers. Our proprietary SG4D10B foundation model, trained on 10 billion compounds across 100+ tasks, captures four-dimensional molecular information for unprecedented prediction accuracy. Unlike repurposed language models, our architecture was built specifically for molecular science, delivering superior performance even with minimal training data. [PROVEN RESULTS ACROSS INDUSTRIES] Our technology has delivered transformative ROI through real-world applications: * Pharmaceutical Partners: Virtual screening of 38 billion compounds identified a novel MKNK2 inhibitor in just 3 months instead of 12, with 90% cost reduction * Beverage Industry: Reduced discovery timelines for functional ingredients from 5 years to 6 months, identifying 10 active candidates from a 250M compound library * Environmental Solutions: Discovered novel PET-degrading enzymes outperforming existing plastic recycling solutions Chemical Manufacturing: Identified enzymatic pathways enabling sustainable production processes These successes demonstrate our consistent ability to accelerate molecular discovery by 75% while reducing costs by 90% compared to traditional approaches. [FLEXIBLE BUSINESS MODELS] SyntheticGestalt offers engagement options tailored to client needs: * Foundation Model Access: Enterprise subscription to SG4D10B via AWS and Google Cloud Marketplaces * Strategic Research Collaborations: Fixed-fee discovery programs or milestone-based development partnerships * Compound Discovery: Direct IP transfer of novel molecules identified through our AI platform Our multidisciplinary team of AI experts, medicinal chemists, and computational biologists works directly with partners to maximize value delivery. [UNIQUE TECHNOLOGY ADVANTAGES] What sets our approach apart: * World’s Largest Molecular AI: Trained on 10 billion compounds—orders of magnitude beyond competitors * True 4D Representation: Captures complete structural and electronic properties for superior prediction accuracy * Minimal Data Requirements: Achieves high performance with significantly smaller datasets than traditional AI * Cross-Domain Applications: From small molecule drugs to industrial enzymes, materials, and beyond [APPLICATIONS BEYOND PHARMACEUTICALS] While pharmaceutical applications deliver dramatic ROI, our technology drives innovation across multiple industries: * Chemical Manufacturing: Enzyme discovery for greener production processes * Materials Science: Novel materials with precisely engineered properties * Agrichemicals: Safer, more effective crop protection solutions * Food & Beverage: Functional ingredients with targeted properties * Fragrance: Prediction of sensory characteristics in aroma compounds [GLOBAL EXPANSION] With successful partnerships in Japan with major corporations including Enamine and Asahi Group, we’re now expanding internationally, raising Series B funding to accelerate U.S. market entry. Our vision extends to designing multi-component molecular systems, optimizing synthetic pathways, predicting complex biological interactions, and creating autonomous discovery platforms—dramatically accelerating scientific innovation. [PARTNER WITH US AT BIO INTERNATIONAL 2025] Visit us at Booth #2265 in the Japan Pavilion or schedule a meeting through the BIO Partnering System to discuss: * How our technology can transform your specific R&D challenges * Collaborative research opportunities * Foundation model access options Join the organizations already leveraging our technology to achieve breakthrough results in molecular discovery with 90% less cost and 75% less time. [CONTACT INFORMATION] Location: Japan Pavilion, Booth #2265 Website: https://syntheticgestalt.com/en Email: d.morohashi@syntheticgestalt.com Partnering Contact: Daisuke Morohashi, Head of AI Business
Syngene International
Syngene International Ltd. is a leading Integrated Innovation Partner and CRDMO, for the global pharmaceutical, biopharma, biotechnology, and life sciences investment sectors. By combining discovery science, development expertise, and scalable manufacturing under one roof, we eliminate handoff delays, anticipate technical challenges, and align strategies to shorten timelines and reduce risk. As an innovation partner, we connect every stage from concept to IND. With expertise across biologics, ADCs, and targeted protein degradation, we deliver speed, scientific depth, and strategic alignment. Our proprietary SynTACs™ platform advances induced proximity-based therapeutics such as PROTACs, while our AI-driven ecosystem—Syn.AI™, SARchitect™, and SynTIPS™—optimizes design, accelerates analysis, and delivers actionable insights. Powered by our SynVent™ integrated discovery engine, we transform early-stage ideas into viable clinical candidates. Through versatile partnering structures and tailored business models, Syngene supports more than 400 global customers—including leading biotech innovators and multinational companies such as BMS, GSK, Zoetis, and Merck KGaA—to accelerate drug pipelines with capital efficiency, scientific rigor, and world-class manufacturing excellence. | . | Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene’s more than 5000 scientists offer both skills and the capacity to deliver great science, robust data security, and world-class manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist facilities, Syngene works with biotech companies pursuing leading-edge science, such as GSK, Zoetis, and Merck KGaA. | Specialization – Syngene offers end-to-end services for mammalian and microbial systems, covering diverse modalities and therapeutic areas. This primarily includes mAbs, recombinant proteins, bispecific, biosimilars, and ADCs. About us – Syngene, a leading global CRDMO with over 30 years of experience solving complex R&D challenges, delivers integrated drug discovery, development, and manufacturing services across small and large molecules. Its diverse clientele ranges from global multinationals to small and medium-sized start-ups. Syngene helps biopharma companies accelerate large molecule therapies to market through integrated biologics CDMO services, with manufacturing facilities across the U.S. and India. With a GMP capacity of 50 KL in single-use bioreactors, featuring 500-, 2,000-, and 4,000-liter units designed to deliver economies of scale, Syngene offers innovative, flexible, and efficient solutions to its clientele.
Stämm
Stämm is an international biotechnology company that is revolutionizing the way biomanufacturing is done. Founded in 2016, it’s now based in the United States and has offices and labs in Argentina and Switzerland. The company offers advanced solutions for automated, continuous, and improved biologics & cell therapies production with a wide range of solutions that stem from their core solution, the Bioprocessor, to cell line development and an AI transomics platform. Stämm’s mission is to make bioprocesses easy, scalable, sustainable and repeatable inspired by nature’s solutions, unleashing the full potential of biotechnology and thus freeing their partners to focus on the disruptive discoveries that make an impact in people’s lives. The company is committed to providing the best possible solutions to accelerate life-changing therapies through flexible, future-ready facilities that meet the evolving needs of its clients and improve global health. Products & Services Stämm’s products and services are structured in three segments: 1. Biomanufacturing: Stämm’s core solution is a continuous, bubble-free Bioprocessor, a biomanufacturing platform with a novel 3D printed bioreactor that enhances yields, reduces costs, and minimizes footprint and energy consumption. Stämm’s approach enables a scalable,energy-efficient solution that provides an ideal cell growth environment. 2. Bio AI: Stämm is developing a transomics platform that leverages in-silico methods through their Multi-omic Network Atlas (MoNA™) allowing to map the biomolecular behaviour of cells with its experimental ambient conditions. With MoNA, biotechnologists and molecular biologists will be able to reduce the uncertainty and risk during wet-lab assay design, execution and interpretation. Therefore achieving high precision biomolecular decision-making. 3.Bioenegineering: Stämm is developing state-of-the-art devices for Cell Line Development with automated cell engineering, clone outgrowth & screening for production of biologics. This is being done through a Bioengineering Platform, an engineering and sorting platform powered by a high-throughput automated system to streamline your workflow and a Clone Selection Platform, a specialized solution that automates clone selection and screening, monitoring the process to optimize your pipeline. Stämm’s is committed to providing a bio-innovative perspective capable of tackling the entire biomanufacturing pipeline
Staburo GmbH
Staburo GmbH is a data science company, specialized in biostatistics, programming (with R and SAS), data management and bioinformatics for healthcare projects. Our core competencies include Clinical Statistics, Translational Medicine & Biomarkers, Phase I, Data Transparency & Disclosure Services and Bioinformatics. Our customers are CROs (with small or no biometry department inhouse), biotech companies, international pharmaceutical companies (7 of the top 20) and medical device manufacturers.
SmartLabs
SmartLabs is challenging the status quo by delivering flexible turnkey lab programs to support workflows at every stage of development. Our transformative solutions include enterprise-grade lab environments, expert guidance, and the daily operational support you need every step of the way. | SmartLabs accelerates scientific breakthroughs by delivering cutting-edge, flexible laboratory infrastructure and comprehensive operational support. Addressing the global demand for state-of-the-art research facilities, SmartLabs provides a range of solutions, including move-in-ready suites, customized spaces, and an innovative franchise model that empowers life science innovators and investors worldwide to establish and operate advanced research environments. SmartLabs is expanding access to state-of-the-art lab facilities. This expansion enables regions worldwide to foster their own thriving research ecosystems. Building upon its established expertise, SmartLabs offers a solution that enables global real estate developers and investors to establish state-of-the-art research facilities in underserved markets. This model provides: Turnkey Lab Solutions: Comprehensive design, construction, and operational frameworks for rapidly deploying advanced lab spaces. Customizable Facilities: Lab spaces tailored to meet the specific needs of diverse research and innovation ecosystems Expert Operational Support: Leveraging SmartLabs’ proven track record in managing complex lab environments, franchisees and end-users benefit from comprehensive support in compliance, equipment maintenance, safety, and daily operations. Scalability and Flexibility: Solutions designed to accommodate a wide range of users, from startups to established enterprises, with the ability to adapt to future growth. By combining its existing flexible lab solutions with this innovative franchise approach, SmartLabs is uniquely positioned to address the global demand for advanced research facilities, empowering innovation and driving economic growth in emerging and established markets alike.
simAbs
simAbs is an EU based manufacturer of monoclonal antibodies. With our proprietary platform we are revolutionizing biomanufacturing with continuous flow technology. SimAbs provides the full range of services and support for biologics development and GMP manufacturing, specializing in sustainable biomanufacturing technologies. We are EU-GMP accredited. We are successfully delivering pre-clinical and clinical phase products. Our way to collaborate is flexible and always tailored to meet your business goals. Recently we have expanded our business into US and India and are looking for additional partnerships for global expansion.
SigutLabs s.r.o.
SigutLabs, a contract research organization (CRO) located in Prague, Czech Republic, helps businesses from small start-ups to pharmaceutical giants overcome their chemistry challenges. Our agile PhD chemists specialize in custom synthesis, scale-up, and contract research across organic, bioorganic, and medicinal chemistry, with a focus on nucleotide and nucleoside chemistry, ADC linkers, and advanced applications. We excel at developing novel synthetic routes for undescribed compounds and custom synthesis of known molecules, also offering dedicated FTE chemists. We have a lean team of up to 10 employees with every chemist holding a PhD degree, which is an industry-leading scientific staff ratio. All our experts studied at prestigious universities and have extensive experience in organic and medicinal chemistry from top international institutions. Our cutting-edge labs prioritize a sustainable future with eco-friendly practices and invest in top-tier equipment to handle your most complex projects. Products from our inventory are available for purchase through our e-shop, ensuring super-fast and secure delivery worldwide. Founded in 2011, SigutLabs has grown from a small lab to a partner of choice for leading pharmaceutical and Silicon Valley companies. We played a major role in the fight against COVID-19 by developing a new synthetic pathway of remdesivir for research in just four months, and were recognized for our achievements with the 2023 Company of the Year award (Central Bohemia region). Fueled by a vision to build on the legacy of Czech chemistry, exemplified by Prof. Antonín Holý and his groundbreaking molecule tenofovir, we aim to re-establish the Czech Republic’s position on the global chemistry map. We can tackle your toughest challenges with our team’s diverse chemistry experience, including: ADC linkers Heterocyclic chemistry Palladium-catalyzed reactions Organometallic chemistry Nucleoside/nucleotide chemistry Fluorine chemistry Photochemistry Supramolecular chemistry Total synthesis of natural products Modification of enzyme substrates/inhibitors Visit our website at www.sigutlabs.com to see how SigutLabs frees hands, saves costs, and accelerates your projects with our outsourced chemistry expertise. Follow us on LinkedIn to see the latest news. | x